Abstract
High serum concentration of soluble interleukin-2 receptor (sIL-2R) is considered a reliable marker of T lymphocyte activation. It has been recently reported that sIL-2R levels are increased in untreated Graves’ disease. This finding has been interpreted as the consequence of an active autoimmune state, but the relevance of the thyroid function per se was not investigated. In the present study we assayed sIL-2R by ELISA in 20 normal subjects and in a series of patients with immunogenic (Graves’ disease, GD) or nonimmunogenic (toxic adenoma, TA) hyperthyroidism. Significantly increased concentrations of sIL-2R were found in 46 patients with untreated hyper-thyroid GD (mean ± SD: 1,683 ± 1016 U/ml, vs 461 ± 186 U/ml in normal controls, p < 0.0001) and in 21 with untreated TA (1,111 ± 617 U/ml, p < 0.0001 vs normals). Restoration of the euthyroid state by antithyroid drugs or 131I administration was associated with a normalization of sIL-2R (516 ± 174 U/ml in 38 patients with GD and 365 ± 90 U/ml in 12 with TA; p = NS vs normals and p < 0.001 vs the untreated state for both groups). A highly significant positive correlation between serum sIL-2R and free triiodothyronine (FT3) (r = 0.724, p < 0.0001) or free thyroxine (FT4) (r = 0.698, p < 0.0001) concentrations was found in combined sera obtained from all untreated and treated patients, irrespectively of the autoimmune or nonautoimmune nature of the underlying hyperthyroid disease. No relationship was found between sIL-2R and the presence or the titer of anti-thyroglobulin and anti-thyroid peroxidase autoantibodies. In conclusion, sIL-2R concentrations are increased in immunogenic and nonimmmunogenic hyperthyroidism. This phenomenon prevents the use of sIL-2R as a reliable marker of autoimmune activation in hyperthyroid conditions.
Access this article
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
References
Greene W.C., Depper J.M., Krönke M., Leonard W. The human interleukin-2 receptor: analysis of structure and function. Immunol. Rev. 92: 29, 1986.
Smith K.A. The interleukin 2 receptor. Annu. Rev. Cell. Biol. 5: 397, 1989.
Rubin L.A., Kurman C.C., Fritz M.E., Biddison W.E., Boutin B. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J. Immunol. 135: 3172, 1985.
Rubin L.A., Nelson D.L. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann. Intern. Med. 113: 619, 1990.
Giordano C., Galluzzo A., Marco A., Panto F., Amato M.P., Caruso C., Bompiani G.D. Increased soluble interleukin-2 receptor levels in the sera of type 1 diabetic patients. Diabetes Res. 8: 135, 1988.
Nakanishi K., Taniguchi Y., Onji Y., Yamaguchi S., Tamai M., Ichiba T., Tanaka A., Ohta Y. Increased levels of soluble interleukin 2 receptors in Graves’ disease. 8th International Congress of Endocrinology, Kyoto, Japan, 1988, Abstract 12-18-011.
Chow C.C., Lai K.N., Leung J.C.K., Chan J.C.N., Cockram C.S. Serum soluble interleukin 2 receptor in hyperthyroid Graves’ disease and effect of carbimazole therapy. Clin. Endocrinol. (Oxf.) 33: 317, 1990.
Weryha G., Gobert B., Leclère J., Béné M.C., Faure G. Dynamic changes in soluble interleukin-2 receptor (IL-2R) and interleukin-6 (IL-6) seric levels in patients with Graves’ disease (GD). Program 10th International Thyroid Congress, Jerusalem, Israel, September 9–14, 1990, p. 19, Abstract N. 30.
Marcocci C., Chiovato L., Mariotti S., Pinchera A. Changes of circulating thyroid autoantibody levels during and after therapy with methimazole in patients with Graves’ disease. J. Endocrinol. Invest. 5: 13, 1982.
Weetman P., McGregor A.M., Hall R. Evidence for an effect of antithyroid drugs on the natural history of Graves’ disease. Clin. Endocrinol. (Oxf.) 21: 163, 1984.
Caturegli P., Barbesino G., Del Prete G.F., Pinchera A., Mariotti S. Serum soluble interleukin 2 receptor in thyroid disease. J. Endocrinol. Invest. 14(Suppl. 2): 185, 1991.
Mariotti S., Pinchera A. Role of the immune system in the control of thyroid function. In: Greer M.A. (Ed.), The Thyroid Gland. Raven Press, New York, 1990, p. 147.
Fabris N., Mocchegiani E., Mariotti S., Pacini F., Pinchera A. Thyroid-thymus interactions during development and aging. Horm. Res. 31: 85, 1989.
Sztein M.B., Serrate S.A., Goldstein A.L. Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc. Natl. Acad. Sci. USA 83: 6107, 1986.
Leichtling K.D., Serrate S.A., Stein M.B. Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int. J. Immunopharmacol. 12: 19, 1990.
Harel-Bellan A., Krief P., Rimsky L., Farrar W.L., Mishal Z. Flow cytometry resonance energy transfer suggests an association between low-affinity interleukin 2 binding sites and HLA class I molecules. Biochem. J. 268: 35, 1990.
Lervang H.H., Moller-Petersen J. Serum beta 2-microglobulin levels in thyroid diseases. J. Intern. Med. 226: 261, 1989.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mariotti, S., Caturegli, P., Barbesino, G. et al. Circulating soluble interleukin 2 receptor concentration is increased in both immunogenic and nonimmunogenic hyperthyroidism. J Endocrinol Invest 14, 777–781 (1991). https://doi.org/10.1007/BF03347915
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03347915